Efficacy Of Immune Checkpoint Inhibitors For Treating Uveal Melanoma Metastases

Purpose: To compare survival in patients with metastatic uveal melanoma treated with immune checkpoint inhibitors to patients who received other therapies or no treatment.Methods: We identified 98 patients treated with proton radiation for uveal melanoma in the Ocular Melanoma Center at Massachusetts Eye and Ear who were subsequently diagnosed with metastasis from January 2010 through May 2018 and followed through August 2018. Survival time after metastasis diagnosis was compared between patients who received antibodies to programmed cell death protein 1 (anti-PD-1)(n= 13), cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4)(n= 27), or combination therapy (n= 4) and patients who received other types of treatment (n= 42) or no therapy (n= 13).Results: Mean age of untreated patients was 69.8 years at the time of metastasis diagnosis, compared to 62.6 years for patients receiving anti-PD …